Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 26, 2007. The report details a share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,150,000 Ordinary shares
- Purchase Price: 1,299.31 pence per share
- Treasury Shares Held: 323,074,158 shares (representing 5.67% of total voting rights)
- Shares in Issue: 5,697,741,837 shares (excluding Treasury shares)
Material Changes
The primary material change is the reduction of outstanding shares through the acquisition of 1,150,000 shares for Treasury. Consequently, the total number of shares held in Treasury increased to 323,074,158. The filing does not provide comparative financial data to assess changes in operating performance versus prior periods.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,697,741,837) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (323,074,158) and its impact on total voting rights (5.67%).
- Review the Annual General Meeting minutes from May 23, 2007, to understand the full scope of the share repurchase authority.